Researchers from the University of Houston and University of Michigan in Ann Arbor have developed a dual-target drug designed to overcome immunotherapy resistance in pancreatic cancer.
The research team developed SH-273 and a nanoparticle version, Nano-273, to boost immune system activity against pancreatic ductal adenocarcinoma, according to a May 27 news release. The cancer type has a five-year survival rate of 13%.
The study, published April 28 in Nature Cancer, found that combining STING activation with PI3Kγ inhibition reduced regulatory B cells that can block immune responses against tumors.
In mouse models and patient-derived human cells, Nano-273 improved survival to 201 days, reduced tumor metastasis and invasion in the lungs, and did not show toxicity in animals, the researchers said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
